Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

  • 1
    Publication Date: 2018-12-11
    Description: IL-33 released by epithelial cells and immune cells functions as an alarmin and can induce both type 1 and type 2 immune responses. However, the role of IL-33 release in tumor development is still not clear. In this study, we examined the function of released IL-33 in murine hepatocellular carcinoma (HCC) models by hydrodynamically injecting either IL-33–expressing tumor cells or IL-33–expressing plasmids into the liver of tumor-bearing mice. Tumor growth was greatly inhibited by IL-33 release. This antitumor effect of IL-33 was dependent on suppression of tumorigenicity 2 (ST2) because it was diminished in ST2 –/– mice. Moreover, HCC patients with high IL-33 expression have prolonged overall survival compared with the patients with low IL-33 expression. Further study showed that there were increased percentages and numbers of activated and effector CD4 + and CD8 + T cells in both spleen and liver in IL-33–expressing tumor-bearing mice. Moreover, IFN- production of the CD4 + and CD8 + T cells was upregulated in both spleen and liver by IL-33. The cytotoxicity of CTLs from IL-33–expressing mice was also enhanced. In vitro rIL-33 treatment could preferentially expand CD8 + T cells and promote CD4 + and CD8 + T cell activation and IFN- production. Depletion of CD4 + and CD8 + T cells diminished the antitumor activity of IL-33, suggesting that the antitumor function of released IL-33 was mediated by both CD4 + and CD8 + T cells. Taken together, we demonstrated in murine HCC models that IL-33 release could inhibit tumor development through its interaction with ST2 to promote antitumor CD4 + and CD8 + T cell responses.
    Print ISSN: 0022-1767
    Electronic ISSN: 1550-6606
    Topics: Medicine
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...